| For: | Seo Y, Yano Y. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection. World J Gastroenterol 2014; 20(37): 13284-13292 [PMID: 25309065 DOI: 10.3748/wjg.v20.i37.13284] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i37/13284.htm |
| Number | Citing Articles |
| 1 |
Yoshihiko Yano, Yasushi Seo, Hiroki Hayashi, Yuri Hatazawa, Hirotaka Hirano, Akihiro Minami, Yuki Kawano, Masaya Saito, Toshiaki Ninomiya, Masahiko Sugano, Hajime Yamada, Naoto Kitajima, Seitetsu Yoon, Yoshitake Hayashi. Factors associated with the decrease in hepatitis B surface antigen titers following interferon therapy in patients with chronic hepatitis B: Is interferon and adefovir combination therapy effective?. Biomedical Reports 2017; 7(3) doi: 10.3892/br.2017.944
|
| 2 |
Pascal Mutz, Philippe Metz, Florian A. Lempp, Silke Bender, Bingqian Qu, Katrin Schöneweis, Stefan Seitz, Thomas Tu, Agnese Restuccia, Jamie Frankish, Christopher Dächert, Benjamin Schusser, Ronald Koschny, Georgios Polychronidis, Peter Schemmer, Katrin Hoffmann, Thomas F. Baumert, Marco Binder, Stephan Urban, Ralf Bartenschlager. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. Gastroenterology 2018; 154(6) doi: 10.1053/j.gastro.2018.01.044
|
| 3 |
Jingjing He, Yifei Guo, Yao Zhang, Jiajia Han, Jingwen Chen, Yidi Jia, Zhenxuan Ma, Jingwen Wu, Shenyan Zhang, Fahong Li, Richeng Mao, Jiming Zhang. Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients. Infection and Drug Resistance 2023; doi: 10.2147/IDR.S411183
|
| 4 |
Marlone Cunha-Silva, Fábio R.T. Marinho, Paulo F. Oliveira, Tirzah M. Lopes, Tiago Sevá-Pereira, Sonia L.S. Lorena, Jazon R.S. Almeida. Retrospective analysis of hepatitis B virus chronic infection in 247 patients: clinical stages, response to treatment and poor prognostic factors. The Brazilian Journal of Infectious Diseases 2017; 21(4) doi: 10.1016/j.bjid.2017.03.019
|
| 5 |
Ronghua Ding, Jinzhao Long, Mingzhu Yuan, Xue Zheng, Yue Shen, Yuefei Jin, Haiyan Yang, Hao Li, Shuaiyin Chen, Guangcai Duan. CRISPR/Cas12-Based Ultra-Sensitive and Specific Point-of-Care Detection of HBV. International Journal of Molecular Sciences 2021; 22(9) doi: 10.3390/ijms22094842
|
| 6 |
Huafeng Lin, Gang Li, Xiangwen Peng, Aimin Deng, Lei Ye, Lei Shi, Tuanmei Wang, Jun He. The Use of CRISPR/Cas9 as a Tool to Study Human Infectious Viruses. Frontiers in Cellular and Infection Microbiology 2021; 11 doi: 10.3389/fcimb.2021.590989
|
| 7 |
James Fung, Ching-Lung Lai, Wai-Kay Seto, Man-Fung Yuen. Emerging drugs for the treatment of hepatitis B. Expert Opinion on Emerging Drugs 2016; 21(2) doi: 10.1517/14728214.2016.1162155
|
| 8 |
Chuming Chen, Xiang Zhu, Wenxiong Xu, Fangji Yang, Genglin Zhang, Lina Wu, Yongyuan Zheng, Zhiliang Gao, Chan Xie, Liang Peng. IFNA2 p.Ala120Thr impairs the inhibitory activity of Interferon-α2 against the hepatitis B virus through altering its binding to the receptor. Antiviral Research 2017; 147 doi: 10.1016/j.antiviral.2017.09.015
|
| 9 |
Sheng Ren, Jun Wang, Tie-Long Chen, Hao-Yu Li, Yu-Shun Wan, Nan-Fang Peng, Xi-En Gui, Ying Zhu, Haitao Guo. Hepatitis B Virus Stimulated Fibronectin Facilitates Viral Maintenance and Replication through Two Distinct Mechanisms. PLOS ONE 2016; 11(3) doi: 10.1371/journal.pone.0152721
|
| 10 |
D. Xiang‐Chun, Y. Xiao‐qing, Y. Ting‐Ting, L. Zhen‐Hui, L. Xiao‐Yan, L. Xia, H. Yan‐Chao, Y. Yi‐Xuan, M. Li‐Na. Alpha‐enolase regulates hepatitis B virus replication through suppression of the interferon signalling pathway. Journal of Viral Hepatitis 2018; 25(3) doi: 10.1111/jvh.12813
|
| 11 |
Sidra Abbas, Ayesha Saeed, Monaza Bibi, Shaghufta Perveen, Nosheen Masood. CRISPR-Cas: From bacterial immunity to precision genome engineering. Gene Reports 2025; 40 doi: 10.1016/j.genrep.2025.102296
|
| 12 |
Fumitaka Suzuki, Yoshiyuki Suzuki, Yoshiyasu Karino, Yasuhito Tanaka, Masayuki Kurosaki, Hiroshi Yatsuhashi, Tomofumi Atarashi, Masanori Atsukawa, Tsunamasa Watanabe, Masaru Enomoto, Masatoshi Kudo, Naoto Maeda, Hiroshi Kohno, Kouji Joko, Kojiro Michitaka, Koichiro Miki, Kazuhiro Takahashi, Tatsuya Ide, Shigetoshi Fujiyama, Tomoko Kohno, Hiroshi Itoh, Sakiyo Tsukamoto, Yuko Suzuki, Yoshiaki Kawano, Wataru Sugiura, Hiromitsu Kumada. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study. BMC Gastroenterology 2021; 21(1) doi: 10.1186/s12876-021-02008-9
|
| 13 |
Gargi Bhattacharjee, Indra Mani, Nisarg Gohil, Khushal Khambhati, Darren Braddick, Happy Panchasara, Vijai Singh. Precision Medicine for Investigators, Practitioners and Providers. 2020; doi: 10.1016/B978-0-12-819178-1.00007-1
|
| 14 |
Andrew D. Huber, Dallas L. Pineda, Dandan Liu, Kelsey N. Boschert, Anna T. Gres, Jennifer J. Wolf, Emily M. Coonrod, Jing Tang, Thomas G. Laughlin, Qiongying Yang, Maritza N. Puray-Chavez, Juan Ji, Kamalendra Singh, Karen A. Kirby, Zhengqiang Wang, Stefan G. Sarafianos. Novel Hepatitis B Virus Capsid-Targeting Antiviral That Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores. ACS Infectious Diseases 2019; 5(5) doi: 10.1021/acsinfecdis.8b00235
|
| 15 |
Shyam Tripathi, Purnima Khatri, Zeeshan Fatima, Ramendra Pati Pandey, Saif Hameed. A Landscape of CRISPR/Cas Technique for Emerging Viral Disease Diagnostics and Therapeutics: Progress and Prospects. Pathogens 2022; 12(1) doi: 10.3390/pathogens12010056
|
| 16 |
Hao Li, Chunyu Sheng, Shan Wang, Lang Yang, Yuan Liang, Yong Huang, Hongbo Liu, Peng Li, Chaojie Yang, Xiaoxia Yang, Leili Jia, Jing Xie, Ligui Wang, Rongzhang Hao, Xinying Du, Dongping Xu, Jianjun Zhou, Mingzhen Li, Yansong Sun, Yigang Tong, Qiao Li, Shaofu Qiu, Hongbin Song. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Frontiers in Cellular and Infection Microbiology 2017; 7 doi: 10.3389/fcimb.2017.00091
|
| 17 |
Ronghua Ding, Yue Shen, Mingzhu Yuan, Xue Zheng, Shuaiyin Chen, Guangcai Duan. Rapid and facile detection of HBV with CRISPR/Cas13a. New Journal of Chemistry 2022; 46(41) doi: 10.1039/D2NJ02674K
|
| 18 |
Weidong Zhao, Xian Zhou, Gan Zhao, Qing Lin, Xianzheng Wang, Xueping Yu, Bin Wang. Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model. Human Vaccines & Immunotherapeutics 2017; 13(12) doi: 10.1080/21645515.2017.1344797
|
| 19 |
Mariana Mihăilă, Cătălin Ştefan Ghenea, Livia Marieta Negoiţă. Hepatitis - Recent Advances in 2025. 2024; doi: 10.5772/intechopen.1007625
|